China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
91 hedge funds and large institutions have $1.49B invested in China Biologic Products Holdings, Inc. in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 20 increasing their positions, 35 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
6% more funds holding
Funds holding: 86 → 91 (+5)
1% more capital invested
Capital invested by funds: $1.48B → $1.49B (+$9.65M)
3% less call options, than puts
Call options by funds: $8.24M | Put options by funds: $8.5M
43% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
+$42M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$17.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$9.29M |
| 4 |
PHK
Point72 Hong Kong
Hong Kong
|
+$8.97M |
| 5 |
Man Group
London,
United Kingdom
|
+$6.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Vontobel Asset Management
New York
|
-$63.4M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$52.4M |
| 3 |
Goldman Sachs
New York
|
-$44.3M |
| 4 |
BlackRock
New York
|
-$35.2M |
| 5 |
CGI
Comgest Global Investors
Paris,
France
|
-$34.1M |
CBPO Hedge Fund Activity: Q2 2018 in Review
91 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2018, worth a combined $1.49B — up 0.65% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CBPO positions and 15 closed out — a net gain of 6 holders — while 20 added to existing stakes and 35 trimmed.
The largest buyer was York Capital Management Global Advisors, adding an estimated $42M. The largest seller was Vontobel Asset Management, cutting an estimated $63.4M.
- 91 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2018, up from 86 in Q1 2018.
- Funds reported $1.49B of China Biologic Products Holdings, Inc. stock for Q2 2018, up 0.65% quarter-over-quarter.
- 21 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2018 and 15 closed out, a net change of +6 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q2 2018 was York Capital Management Global Advisors, an estimated $42M added.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2018 was Vontobel Asset Management, an estimated $63.4M sold.
Based on aggregated 13F filings for Q2 2018.